Yes, thank you for taking my question. So my first question is on the India business. So, going forward, assuming the IPM grows at, say, high-single-digits, do you think even on a base which has the in -licensed diabetic product which went off patent, we can still outperform the IPM over the medium -term, or it will be slightly tall?
Okay. And how do you how do you split this or say if you grow at 10% how do we split that out into price and volume?